{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+4+MG&page=2", "query": { "intervention": "Baricitinib 4 MG", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+4+MG&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+4+MG&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T00:15:19.583Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05189106", "title": "Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis", "Alzheimer Disease", "Mild Cognitive Impairment" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 17, "start_date": "2022-12-05", "completion_date": "2025-06-20", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlestown", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05189106" }, { "nct_id": "NCT04901325", "title": "Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pyoderma Gangrenosum", "Skin Diseases", "Wound Heal", "Pyoderma", "Skin Ulcer" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2023-10-03", "completion_date": "2025-05-07", "has_results": false, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04901325" }, { "nct_id": "NCT03570749", "title": "A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 784, "start_date": "2018-09-24", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03570749" }, { "nct_id": "NCT04640168", "title": "Adaptive COVID-19 Treatment Trial 4 (ACTT-4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1010, "start_date": "2020-12-02", "completion_date": "2021-06-18", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640168" }, { "nct_id": "NCT05003310", "title": "ConsideRAte Study - Splenic Stimulation for RA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Active Stimulation", "type": "DEVICE" }, { "name": "Sham Stimulation", "type": "DEVICE" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Background Treatment", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Galvani Bioelectronics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "22 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2021-10-19", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2024-05-22", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 12, "location_summary": "Anniston, Alabama • Covina, California • Whittier, California + 8 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Covina", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05003310" }, { "nct_id": "NCT01721044", "title": "A Moderate to Severe Rheumatoid Arthritis Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "cDMARD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 527, "start_date": "2013-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 32, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01721044" }, { "nct_id": "NCT07209267", "title": "Baricitinib Curative Repression of HIV-1", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "HIV" ], "interventions": [ { "name": "Antiretroviral Therapy (ART)", "type": "DRUG" }, { "name": "Baricitinib (LY3009104) 2 mg", "type": "DRUG" }, { "name": "Baricitinib (LY3009104) 4 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 35, "start_date": "2026-10", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209267" }, { "nct_id": "NCT01490632", "title": "A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis", "Skin Diseases", "Skin Diseases, Papulosquamous" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2011-12", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2019-09-27", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 18, "location_summary": "Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490632" }, { "nct_id": "NCT01711359", "title": "A Study in Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Baricitinib Placebo", "type": "DRUG" }, { "name": "MTX Placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2012-11", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 47, "location_summary": "Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711359" }, { "nct_id": "NCT01710358", "title": "A Study in Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Adalimumab Placebo", "type": "DRUG" }, { "name": "Baricitinib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1307, "start_date": "2012-10", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-01T00:15:19.583Z", "location_count": 45, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01710358" } ] }